Compared with patients without KRAS, TP53 or CDKN2A alterations, MMP14 and PKM2 were highly expressed in pancreatic cancer patients with KRAS, TP53 or CDKN2A alterations (Figure 4C). Here, CDKN2A is linked to pancreatic neoplasm.